Arrowhead Pharma (NASDAQ:ARWR) Stock

ARROWHEAD PHARMACEUTICALS IN

Arrowhead Pharma

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025.

News

ARWR

Arrowhead Wraps Enrollment for 3 Key Trials on Fat-Busting Drug, Eyes FDA Decision in November

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Dover Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>).
Supporting his view, Dover, on April 24, posted better-than-expected <a href="https://www.benzinga.com/quote/DOV">earnings for the first quarter</a>.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) doesn&#8217;t make any money, Cramer said. &#8220;I just don&#8217;t know if it has the horses.&#8221;
As per the recent news, Arrowhead Pharmaceuticals, on Monday, initiated Phase 1/2a study of ARO-ALK7 for the treatment of obesity.
Cramer said Snowflake Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NASDAQ">SNOW</a>) CEO Sridhar Ramaswamy is &#8220;cerebral, and he's got a real good closing sense, and man, does he ever have momentum.&#8221;
Supporting his view, Snowflake, on May 21, reported first-quarter revenue of $1.04 billion, beating analyst estimates of $1.01 billion. The AI data cloud company reported adjusted earnings of 24 cents per share, beating analyst estimates of 21 cents per share, according to Benzinga Pro.
Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) is &#8220;always a bridesmaid, never a bride,&#8221; Cramer said.
On the earnings front, Fluor, on May 2, posted mixed first-quarter 2025 results, with key metrics surpassing some expectations. Fluor&#8217;s revenue grew 6.6% year-over-year to $3.982 billion, missing the consensus of $4.18 billion. Adjusted EPS improved to 73 cents from 47 cents a year ago, above the consensus of 50 cents.
Price Action:
<ul class="wp-block-list">
<li>Arrowhead Pharmaceuticals shares gained 1.3% to settle at $16.61 on Tuesday.</li>
<li>Snowflake shares fell 0.5% to close at $209.15.</li>
<li>Dover shares gained 1.1% to close at $177.97.</li>
<li>Fluor shares gained 5.4% to settle at $43.39 on Tuesday.</li>
</ul>
Read Next<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">: </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Markets

Media

Trading Ideas

SNOW

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

<ul>
<li>ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue</li>
<li>Study initiation highlights Arrowhead's leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM&#x2122;) platform</li>
<li>In preclinical studies, ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>
Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes.

Arrowhead Pharma Doses First Subjects In Phase 1/2a Clinical Trial Of ARO-ALK7, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Obesity

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Citigroup analyst Shawn Egan maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Neutral and lowers the price target from $21 to $17.

Citigroup Maintains Neutral on Arrowhead Pharma, Lowers Price Target to $17

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Tuesday.
Shares of Archer Aviation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/ACHR/earnings">first-quarter EPS results</a>.
Archer reported a smaller-than-expected loss for the first quarter, posting a 17-cent loss versus estimates for a loss of 28 cents, per Benzinga Pro.
Archer Aviation shares jumped 21.5% to $11.05 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped 27% to $3.0350 after the company reported better-than-expected first-quarter sales results.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) gained 26.8% to $12.05 after the company issued FY25 sales guidance with its midpoint above estimates.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) rose 23.1% to $8.42.</li>
<li>Archer Aviation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>) gained 21.5% to $11.05 after the company reported better-than-expected first-quarter EPS results.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) rose 19.4% to $186.60. Wolfe Research analyst Steve Fleishman upgraded First Solar from Peer Perform to Outperform and announced a $221 price target.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) rose 18% to $17.92 following first-quarter results.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) gained 17.3% to $6.29 following first-quarter results.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) gained 17% to $12.82.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 17% to $20.82 following better-than-expected quarterly sales.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose 17% to $242.63 after it was announced that the company will join the S&amp;P 500, effective before the opening of trading on Monday, May 19.</li>
<li>Life360, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) gained 16.4% to $57.61 following upbeat quarterly results.</li>
<li>Green Plains Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) rose 14.4% to $5.32.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rose 12.1% to $37.58. Raymond James analyst Simon Leopold initiated coverage on Super Micro Computer with an Outperform rating and announced a price target of $41.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) gained 11.6% to $56.51.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) rose 10% to $31.73.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) rose 8.6% to $15.17 after the company reported better-than-expected quarterly financial results.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) gained 8% to $153.75 after the company reported better-than-expected first-quarter EPS results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

ACHR

ARRY

COIN

FSLR

GPRE

HNRG

LUNR

MVST

OKLO

SHLS

SMCI

Archer Aviation Posts Narrower-Than-Expected Loss, Joins Microvast, Intuitive Machines And Other Big Stocks Moving Higher On Tuesday

WIIM

Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Shares of Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose sharply in <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45365186/coinbase-stock-jumps-nearly-11-after-hours-monday-heres-why">today's pre-market trading</a>.
Coinbase is set to join the S&amp;P 500, replacing Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) in the benchmark index, according to a Monday announcement. The inclusion of Coinbase in the S&amp;P 500 will become effective before trading begins on May 19, according to a press release shared by S&amp;P Dow Jones Indices.
Coinbase shares jumped 9.2% to $226.29 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lichen International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) rose 133.6% to $8.13 in pre-market trading after gaining 5% on Monday.</li>
<li>Inno Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) surged 75.8% to $4.15 in pre-market trading. INNO HOLDINGS shares dipped 56% on Monday after the company announced a strategic cooperation with New Life Technology Development on developing a B2B marketplace platform.</li>
<li>Landsea Homes Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) gained 58.5% to $11.12 in pre-market trading after New Home Co. agreed to acquire the company for $11.30 per share in an all-cash transaction. Landsea Homes also reported a narrower-than-expected quarterly loss.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) jumped 42.1% to $0.1706 in pre-market trading after gaining 5% on Monday.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) gained 32.8% to $0.9701 in pre-market trading. The company recently posted downbeat quarterly results.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) surged 24.5% to $0.3102 in pre-market trading after gaining more than 43% on Monday.</li>
<li>Profound Medical Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) climbed 23.5% to $5.30 in pre-market trading. The company recently posted downbeat first-quarter results.</li>
<li>GigaCloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) gained 11.6% to $17.74 in pre-market after the company reported better-than-expected first-quarter financial results.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 10% to $15.36 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 92% to $0.0281 in pre-market trading. Polyrizon recently announced its planned reverse split will not be effected.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) fell 48.8% to $0.67 in pre-market trading after jumping 290% on Monday.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) fell 32.3% to $0.5055 in today's pre-market trading following weaker-than-expected first-quarter results.</li>
<li>Kearny Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) shares dipped 23.5% to $5.00 in pre-market trading after gaining 3% on Monday.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares fell 20.7% to $2.02 in pre-market trading after the company posted weaker-than-expected quarterly results.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) dipped 18.2% to $11.15 in pre-market trading. KindlyMD shares jumped 251% on Monday after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) fell 18% to $0.11 in pre-market trading after dipping 9% on Monday. Accelerate Diagnostics recently announced it filed for Chapter 11 bankruptcy protection.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares tumbled 17% to $0.1448 in pre-market trading after gaining 5% on Monday.</li>
<li>Heritage Commerce Corp (NASDA: HTBK) declined 15.4% to $8.00 in pre-market trading.</li>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) fell 12.1% to $10.15 in pre-market trading after the company reported mixed first-quarter financial results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

AXDX

CGBS

DEVS

HTBK

INHD

KDLY

KLTO

KRNY

LICN

LSEA

PLRZ

PROF

RGTI

SGMO

WLGS

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $(0.16) by 1818.75 percent. This is a 369.61 percent increase over losses of $(1.02) per share from the same period last year. The company reported quarterly sales of $542.71 million which beat the analyst consensus estimate of $29.91 million by 1.71K percent.

Earnings

Earnings Beats

Arrowhead Pharma Q2 EPS $2.75 Beats $(0.16) Estimate, Sales $542.71M Beat $29.91M Estimate

ACHC

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Arrowhead Pharma to report an earnings per share (EPS) of $-0.46.
Anticipation surrounds Arrowhead Pharma's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.67, leading to a 5.17% drop in the share price on the subsequent day.
Here's a look at Arrowhead Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.72</td>
<td>-0.92</td>
<td>-0.55</td>
<td>-0.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.39</td>
<td>-1.37</td>
<td>-1.38</td>
<td>-1.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>24.0%</td>
<td>-9.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746802897_0.png" alt="eps graph" />
<h3>Performance of Arrowhead Pharma Shares</h3>
Shares of Arrowhead Pharma were trading at $13.25 as of May 08. Over the last 52-week period, shares are down 39.66%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ARWR/earnings">To track all earnings releases for Arrowhead Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Arrowhead Pharma's Quarterly Earnings

On, April 9, 2025 Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the "Company") of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025 (the "Effective Date"). Mr. Myszkowski has served as the Company's Chief Financial Officer since 2009, and the Company extends its gratitude to Mr. Myszkowski for his years of service and contributions to the Company. Mr. Myszkowski's decision to retire was not the result of any disagreement with the Company.
 &nbsp;
Following the Effective Date, Mr. Myszkowski will serve as an employee adviser and provide transition services, as requested by the Company, to facilitate an effective transition of his job responsibilities to his successor, until January 31, 2026 (the "Transition Period"). In consideration for such services, Mr. Myszkowski will receive (i) a base salary at an annual rate of $200,000 through the end of the Transition Period, subject to his continued employment, (ii) continued eligibility to participate in the Company's medical, dental and life insurance benefit plans through the end of the Transition Period, subject to continued employment, and (iii) continued vesting of certain outstanding equity awards.
 &nbsp;
Appointment of Chief Financial Officer
 &nbsp;
On April 9, 2025, the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company, effective as of May 13, 2024, until the earliest of Mr. Apel's removal, termination, or resignation from such office.
 &nbsp;

Management

Arrowhead Pharmaceuticals' Ken Myszkowski To Retire As CFO; Daniel Apel Appointed As New CFO

On Monday, Arrowhead Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company&#8217;s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44216024/arrowhead-pharmaceuticals-announces-topline-results-from-part-2-of-phase-12-study-of-aro-c3-in-pat" rel="noreferrer noopener">complement-mediated diseases</a>.
ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases.&nbsp;
The dysregulated activity of the complement system can contribute to tissue injury and the progression of the disease. By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating the activation of the complement cascade.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44223155/veren-soars-on-whitecap-merger-deal-details" rel="noreferrer noopener">Veren Soars On Whitecap Merger Deal: Details</a>
The company plans to present additional results at a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44216024/arrowhead-pharmaceuticals-announces-topline-results-from-part-2-of-phase-12-study-of-aro-c3-in-pat" rel="noreferrer noopener">medical meeting in 2025</a>.
Select Phase 1/2 Study Results
<ul>
<li>Pharmacodynamic effects: Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24.</li>
<li>Maximum mean reduction in serum AH50 (alternative pathway hemolytic assay) of 85% and mean sustained reduction greater than 76%.</li>
<li>Maximum mean reduction in Wieslab AP (alternative pathway) of 100% and mean sustained reduction greater than 89%.</li>
<li>Duration of effect supportive of once every three months or less frequent subcutaneous dosing in later-stage studies</li>
<li>Effects on proteinuria (too much protein in the urine): The mean reduction in spot UPCR was 41%, and the maximum individual reduction was 89%.</li>
</ul>
In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals&#8217; New Drug Application for investigational plozasiran for familial chylomicronemia syndrome, a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43067733/arrowhead-pharmaceuticals-announces-acceptance-of-new-drug-application-by-u-s-fda-of-plozasiran-fo" rel="noreferrer noopener">advisory committee meeting</a>.
In February, Arrowhead Pharmaceuticals closed a global licensing and collaboration agreement with Sarepta Therapeutics Inc. Arrowhead receives a $500 million upfront payment and $325 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43591315/arrowhead-pharmaceuticals-announces-closing-of-global-license-and-collaboration-agreement-with-sar" rel="noreferrer noopener">through Sarepta stock</a>.
Price Action: ARWR stock is down 8.72% at $15.49 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44220746/pfizers-covid-19-shot-partner-biontech-reports-q4-profit-but-2025-guidance-falls-short-on-expectations" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations</a></li>
</ul>
Photo via Shutterstock.

Biotech

Equities

Health Care

General

SRPT

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Arrowhead Pharmaceuticals shares are trading lower after the company announced its topline results from part 2 of phase 1/2 study of aro-c3 in patients with iga nephropathy.

<ul>
<li>ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria.</li>
<li>Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24.</li>
<li>Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24</li>
</ul>

Arrowhead Pharmaceuticals Announced Topline Results From Part 2 Of A Phase 1/2 Study Of ARO-C3 To Reduce Liver Production Of Complement Component 3 As A Potential Therapy For Various Complement Mediated Diseases

&nbsp;
- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies
- Data highlight Arrowhead's leadership in the use of RNA interference to potentially treat Obesity

Events

Arrowhead Pharmaceuticals Presents Preclinical Data Supporting ARO-INHBE and ARO-ALK7 To Treat Obesity And Metabolic Diseases

Arrowhead Pharmaceuticals Presented Preclinical Data On ARO-ALK7 At Keystone Symposia on Obesity and Adipose Tissue

B. Riley Securities analyst Mayank Mamtani reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and lowers the price target from $51 to $38.

B. Riley Securities Reiterates Buy on Arrowhead Pharma, Lowers Price Target to $38

Press Releases

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Comments

Arrowhead Pharma

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL